Testagen

Mechanism

Testagen is a four-amino-acid peptide bioregulator developed to support testicular function and healthy testosterone production by restoring gene activity in the Leydig cells of the testes. Rather than introducing external hormones, it works by reactivating your body's own natural testosterone-producing machinery at the genetic level, making it a gentler alternative to hormone replacement therapy. It may also support sperm quality and overall male reproductive health as part of the Khavinson bioregulator peptide approach to aging.

Effects

## Endocrine System — Testosterone Production [Tier 3 — Limited Human Data, Russian Clinical Studies] Testagen (Asp-Glu-Asp-Leu, tetrapeptide) is a Khavinson bioregulator peptide targeting Leydig cells and the hypothalamic-pituitary-gonadal (HPG) axis. In Russian clinical studies, Testagen reportedly normalizes testosterone production in men with age-related decline by modulating gene expression in testicular tissue. The proposed mechanism involves epigenetic regulation of steroidogenic enzyme expression (StAR protein, CYP11A1, 3β-HSD, 17β-HSD) rather than direct hormonal stimulation. Unlike exogenous testosterone, Testagen is claimed not to suppress endogenous LH/FSH via negative feedback — it reportedly normalizes the axis rather than replacing it. ## Reproductive System [Tier 3 — Limited Human Data] In Russian clinical studies on men aged 50-70+, Testagen administration was associated with improved spermatogenesis parameters, increased sperm count and motility, and improved libido. These effects are attributed to normalized testosterone levels and direct support of Sertoli cell function. ## Musculoskeletal System [Tier 3 — Theoretical] By normalizing testosterone levels, Testagen may indirectly support muscle protein synthesis, bone mineral density, and lean body mass — all testosterone-dependent outcomes. No direct studies on these endpoints.

Practitioner Guide

## Clinical Context Testagen is part of the Khavinson bioregulator peptide system from the St. Petersburg Institute of Bioregulation and Gerontology. It is not approved by the FDA, EMA, or any Western regulatory agency. The claimed ability to restore testosterone production without suppressing the HPG axis would be remarkable if validated, but rigorous Western clinical trials are absent. ### Typical Protocols (From Russian Clinical Literature) - **Oral capsules:** 10 mg daily for 10-30 days. Cycled — 10-day course, 2-3 month break, repeat. - **Combination:** Often combined with Prostatilen/Libidon (prostate bioregulators) for comprehensive male reproductive support. - **Target populations:** Men aged 45+ with age-related testosterone decline, men with mild hypogonadism who prefer non-hormonal approaches. ### Practitioner Considerations - The claim that Testagen "normalizes" testosterone without HPG suppression is the key differentiator from TRT. This would be enormously valuable if proven — but the evidence is limited to small Russian studies. - Do NOT use Testagen as a substitute for TRT in men with clinically significant hypogonadism (total testosterone <300 ng/dL with symptoms). Standard TRT remains the evidence-based treatment. - May be of interest as an adjunctive therapy for men with borderline testosterone (300-400 ng/dL) who want to avoid TRT, though evidence is insufficient to make a strong recommendation. - Monitor: Total and free testosterone, LH, FSH, SHBG before and 30 days after a Testagen course to assess any objective hormonal change. - No known drug interactions. Theoretical concern about interaction with aromatase inhibitors, SERMs, or GnRH analogs — avoid combining without monitoring. - Safety profile appears benign in available literature, but the database is very small.

Dosing Protocols

Contraindications & Cautions

• hard stop — Pregnancy
  Testagen modulates testosterone production. Androgen-influencing compounds are contraindicated in pregnancy due to risk of virilization of female fetuses and disruption of fetal hormonal development.
  Action: Do not use during pregnancy. Absolutely contraindicated.
• hard stop — Breastfeeding
  No data on excretion in breast milk. Testosterone-modulating effects could impact nursing infant hormonal development.
  Action: Do not use while breastfeeding.
• hard stop — Hormone-sensitive cancers (prostate, breast)
  Testagen upregulates testosterone biosynthesis. Testosterone and its metabolites (DHT, estradiol) promote growth of hormone-sensitive tumors including prostate and breast cancer.
  Action: Do not use in patients with active or history of hormone-sensitive cancers. Obtain oncologist clearance for cancer survivors.
• hard stop — Under 18 years of age
  Peptide protocols are not designed for pediatric use. Androgen-modulating peptides may disrupt pubertal development.
  Action: Do not provide to individuals under 18.
• caution — General use
  Limited human safety data. Russian bioregulator peptide without large-scale clinical trials or international regulatory approval.
  Action: Use with awareness of limited evidence base. Monitor testosterone levels and PSA.

Research Summary

## Tier 1 — Strong Clinical Evidence - None. No Western regulatory approval. No international Phase III RCTs. ## Tier 2 — Moderate Evidence - Russian clinical studies (Khavinson et al.) report improved serum testosterone levels in men aged 50-70+ after 10-30 day oral courses (typical improvement: 15-30% increase from baseline, small sample sizes n=20-40) - Reported improvements in spermatogenesis parameters (sperm count, motility) in small clinical studies - No reported HPG suppression (LH/FSH remained normal or increased), supporting the "normalization" rather than "replacement" claim ## Tier 3 — Preclinical/Theoretical - In vitro studies show Testagen tetrapeptide interacts with DNA in Leydig cell nuclei, modulating steroidogenic enzyme gene expression - Cell culture data showing increased StAR protein and CYP11A1 expression in Leydig cells exposed to Testagen - Proposed epigenetic mechanism consistent with other Khavinson bioregulators - All research from single research group — independent replication absent - Oral bioavailability of tetrapeptide not independently confirmed